In the second episode of our ESMO Congress 2024 series, our hosts discuss both non-muscle invasive and muscle-invasive bladder cancer, along with other data that impacts the spectrum of urothelial cancer diagnosis and treatment. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related